Half-year report · HY
3034.TEDINET S100X3IM
Period2025-04-01 → 2025-09-30
Filed2025-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥142.2bn | 2025-04-01 → 2025-09-30 | Cons. | Net sales |
| Revenue | ¥264.0bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥124.8bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Operating income | ¥7.2bn | 2025-04-01 → 2025-09-30 | Cons. | Operating income |
| Operating income | ¥6.1bn | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Ordinary income | ¥7.3bn | 2025-04-01 → 2025-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥13.8bn | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥6.2bn | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥7.1bn | 2025-04-01 → 2025-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥5.0bn | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥3.5bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥5.2bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥1.2bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥4.2bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss |
| Net income | ¥2.3bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Total assets | ¥152.4bn | at 2025-09-30 | Cons. | Assets |
| Total assets | ¥159.7bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥137.3bn | at 2024-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥96.1bn | at 2025-09-30 | Cons. | Liabilities |
| Total liabilities | ¥97.5bn | at 2025-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥56.3bn | at 2025-09-30 | Cons. | Net assets |
| Net assets / equity | ¥62.1bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥58.0bn | at 2024-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥18.3bn | at 2025-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥26.7bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥17.9bn | at 2025-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥26.4bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥21.5bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥26.9bn | at 2024-03-31v | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥6.2bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥12.6bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥477m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥1.0bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥20.4bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥265m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥13.7bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥7.2bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥6.2bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥94.51 | 2025-04-01 → 2025-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥137.97 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥32.43 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 35.7% | at 2025-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 35.8% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 39.3% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 36
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2025-04-01 → 2025-09-30 | −¥721m |
| Reconciling Itemsreconciling | revenue intersegment | 2025-04-01 → 2025-09-30 | −¥721m |
| Reconciling Itemsreconciling | segment profit | 2025-04-01 → 2025-09-30 | −¥1.9bn |
| Health Insurance Pharmacyreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥86.8bn |
| Health Insurance Pharmacyreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥86.7bn |
| Health Insurance Pharmacyreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥76m |
| Health Insurance Pharmacyreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥4.1bn |
| Medical Relatedreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥7.7bn |
| Medical Relatedreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥7.1bn |
| Medical Relatedreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥644m |
| Medical Relatedreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥1.0bn |
| Pharmaceutical Businessreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥48.4bn |
| Pharmaceutical Businessreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥48.4bn |
| Pharmaceutical Businessreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥4.0bn |
| —segment total | revenue | 2025-04-01 → 2025-09-30 | ¥143.0bn |
| —segment total | revenue external | 2025-04-01 → 2025-09-30 | ¥142.2bn |
| —segment total | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥721m |
| —segment total | segment profit | 2025-04-01 → 2025-09-30 | ¥9.1bn |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | −¥686m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2024-09-30 | −¥686m |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥1.8bn |
| Health Insurance Pharmacyreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥84.1bn |
| Health Insurance Pharmacyreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥84.1bn |
| Health Insurance Pharmacyreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥64m |
| Health Insurance Pharmacyreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥4.2bn |
| Medical Relatedreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥7.4bn |
| Medical Relatedreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥6.8bn |
| Medical Relatedreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥622m |
| Medical Relatedreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥928m |
| Pharmaceutical Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥33.9bn |
| Pharmaceutical Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥33.9bn |
| Pharmaceutical Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥2.7bn |
| —segment total | revenue | 2024-04-01 → 2024-09-30 | ¥125.5bn |
| —segment total | revenue external | 2024-04-01 → 2024-09-30 | ¥124.8bn |
| —segment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥686m |
| —segment total | segment profit | 2024-04-01 → 2024-09-30 | ¥7.9bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 549
| Item | Context | Value | Unit |
|---|---|---|---|
| Transactions with other segments | Prior1InterimDuration_jpcrp040300-ssr_E03476-000PharmaceuticalBusinessReportableSegmentMember | － | JPY |
| Transactions with other segments | Prior1InterimDuration_ReportableSegmentsMember | 686000000 | JPY |
| Transactions with other segments | Prior1InterimDuration_ReconcilingItemsMember | -686000000 | JPY |
| Transactions with other segments | Prior1InterimDuration | － | JPY |
| Net sales | Prior1InterimDuration_jpcrp040300-ssr_E03476-000HealthInsurancePharmacyReportableSegmentsMember | 84144000000 | JPY |
| Net sales | Prior1InterimDuration_jpcrp040300-ssr_E03476-000MedicalRelatedReportableSegmentMember | 7377000000 | JPY |
| Net sales | Prior1InterimDuration_jpcrp040300-ssr_E03476-000PharmaceuticalBusinessReportableSegmentMember | 33936000000 | JPY |
| Net sales | Prior1InterimDuration_ReportableSegmentsMember | 125458000000 | JPY |
| Net sales | Prior1InterimDuration_ReconcilingItemsMember | -686000000 | JPY |
| Net sales | Prior1InterimDuration | 124771000000 | JPY |
| Operating income | Prior1InterimDuration_jpcrp040300-ssr_E03476-000HealthInsurancePharmacyReportableSegmentsMember | 4232000000 | JPY |
| Operating income | Prior1InterimDuration_jpcrp040300-ssr_E03476-000MedicalRelatedReportableSegmentMember | 928000000 | JPY |
| Operating income | Prior1InterimDuration_jpcrp040300-ssr_E03476-000PharmaceuticalBusinessReportableSegmentMember | 2742000000 | JPY |
| Operating income | Prior1InterimDuration_ReportableSegmentsMember | 7904000000 | JPY |
| Operating income | Prior1InterimDuration_ReconcilingItemsMember | -1807000000 | JPY |
| Operating income | Prior1InterimDuration | 6096000000 | JPY |
| Revenues from external customers | InterimDuration_jpcrp040300-ssr_E03476-000HealthInsurancePharmacyReportableSegmentsMember | 86734000000 | JPY |
| Revenues from external customers | InterimDuration_jpcrp040300-ssr_E03476-000MedicalRelatedReportableSegmentMember | 7053000000 | JPY |
| Revenues from external customers | InterimDuration_jpcrp040300-ssr_E03476-000PharmaceuticalBusinessReportableSegmentMember | 48443000000 | JPY |
| Revenues from external customers | InterimDuration_ReportableSegmentsMember | 142230000000 | JPY |
| Revenues from external customers | InterimDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | InterimDuration | 142230000000 | JPY |
| Transactions with other segments | InterimDuration_jpcrp040300-ssr_E03476-000HealthInsurancePharmacyReportableSegmentsMember | 76000000 | JPY |
| Transactions with other segments | InterimDuration_jpcrp040300-ssr_E03476-000MedicalRelatedReportableSegmentMember | 644000000 | JPY |
| Transactions with other segments | InterimDuration_jpcrp040300-ssr_E03476-000PharmaceuticalBusinessReportableSegmentMember | － | JPY |
| Transactions with other segments | InterimDuration_ReportableSegmentsMember | 721000000 | JPY |
| Transactions with other segments | InterimDuration_ReconcilingItemsMember | -721000000 | JPY |
| Transactions with other segments | InterimDuration | － | JPY |
| Net sales | InterimDuration_jpcrp040300-ssr_E03476-000HealthInsurancePharmacyReportableSegmentsMember | 86810000000 | JPY |
| Net sales | InterimDuration_jpcrp040300-ssr_E03476-000MedicalRelatedReportableSegmentMember | 7697000000 | JPY |
| Net sales | InterimDuration_jpcrp040300-ssr_E03476-000PharmaceuticalBusinessReportableSegmentMember | 48443000000 | JPY |
| Net sales | InterimDuration_ReportableSegmentsMember | 142951000000 | JPY |
| Net sales | InterimDuration_ReconcilingItemsMember | -721000000 | JPY |
| Net sales | InterimDuration | 142230000000 | JPY |
| Operating income | InterimDuration_jpcrp040300-ssr_E03476-000HealthInsurancePharmacyReportableSegmentsMember | 4052000000 | JPY |
| Operating income | InterimDuration_jpcrp040300-ssr_E03476-000MedicalRelatedReportableSegmentMember | 1002000000 | JPY |
| Operating income | InterimDuration_jpcrp040300-ssr_E03476-000PharmaceuticalBusinessReportableSegmentMember | 4042000000 | JPY |
| Operating income | InterimDuration_ReportableSegmentsMember | 9098000000 | JPY |
| Operating income | InterimDuration_ReconcilingItemsMember | -1915000000 | JPY |
| Operating income | InterimDuration | 7182000000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の５第１項の表の第１号 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 | |
| Filing date cover page | FilingDateInstant | 2025-11-14 | |
| Semi annual accounting period cover page | FilingDateInstant | Original text (Japanese)第34期中 (自 2025年４月１日 至 2025年９月30日) | |
| Company name cover page | FilingDateInstant | Original text (Japanese)クオールホールディングス株式会社 | |
| Company name in english cover page | FilingDateInstant | Qol Holdings Co.,Ltd. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長 中村 敬 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)東京都港区虎ノ門四丁目３番１号 城山トラストタワー37階 | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | 03－6430－9060 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |